Efficacy and safety of rivaroxaban plus clopidogrel versus aspirin plus clopidogrel in patients with coronary atherosclerotic heart disease and gastrointestinal disease undergoing percutaneous coronary intervention: study protocol for a non-inferiority randomized controlled trial

Efficacy and safety of rivaroxaban plus clopidogrel versus aspirin plus clopidogrel in patients with coronary atherosclerotic heart disease and gastrointestinal disease undergoing percutaneous coronary intervention: study protocol for a non-inferiority randomized controlled trial

Highlights 1. To find a more appropriate antithrombotic strategy for patients with CHD and GID undergoing PCI. 2. To identify whether rivaroxaban can reduce the bleeding risk of the gastrointestinal tract compared with aspirin.

Bibliographic Details
Main Authors: Tienan Zhou, Yinghui Gong, Jingyuan Li, Yasong Wang, Xiaozeng Wang
Format: Article
Language:English
Published: BMC 2023-03-01
Series:Trials
Subjects:
Percutaneous coronary intervention
Gastrointestinal disease
Dual antiplatelet therapy
Rivaroxaban
Protocol
Online Access:https://doi.org/10.1186/s13063-023-07236-w

Internet

https://doi.org/10.1186/s13063-023-07236-w

Similar Items